nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—SLC22A5—Dactinomycin—muscle cancer	0.311	0.48	CbGbCtD
Procainamide—SLC22A3—Vincristine—muscle cancer	0.308	0.476	CbGbCtD
Procainamide—CYP2D6—Doxorubicin—muscle cancer	0.0286	0.0442	CbGbCtD
Procainamide—BCHE—diaphragm—muscle cancer	0.0193	0.103	CbGeAlD
Procainamide—SLC22A4—larynx—muscle cancer	0.0158	0.0845	CbGeAlD
Procainamide—DNMT1—Vinblastine—Vincristine—muscle cancer	0.00898	1	CbGdCrCtD
Procainamide—DNMT1—embryo—muscle cancer	0.00565	0.0302	CbGeAlD
Procainamide—SCN7A—cardiac atrium—muscle cancer	0.00499	0.0266	CbGeAlD
Procainamide—SCN11A—head—muscle cancer	0.00438	0.0234	CbGeAlD
Procainamide—SCN4A—renal system—muscle cancer	0.00389	0.0208	CbGeAlD
Procainamide—DNMT1—cardiac atrium—muscle cancer	0.00383	0.0204	CbGeAlD
Procainamide—SCN7A—head—muscle cancer	0.00373	0.0199	CbGeAlD
Procainamide—DNMT1—Regulation of retinoblastoma protein—PAX3—muscle cancer	0.00365	0.0713	CbGpPWpGaD
Procainamide—SCN7A—testis—muscle cancer	0.0036	0.0192	CbGeAlD
Procainamide—SLC22A2—renal system—muscle cancer	0.00357	0.0191	CbGeAlD
Procainamide—SCN9A—tendon—muscle cancer	0.00341	0.0182	CbGeAlD
Procainamide—DNMT1—tendon—muscle cancer	0.00334	0.0178	CbGeAlD
Procainamide—SCN8A—head—muscle cancer	0.00332	0.0177	CbGeAlD
Procainamide—DNMT1—bone marrow—muscle cancer	0.00324	0.0173	CbGeAlD
Procainamide—Hepatomegaly—Dactinomycin—muscle cancer	0.00322	0.0316	CcSEcCtD
Procainamide—SCN8A—testis—muscle cancer	0.00321	0.0171	CbGeAlD
Procainamide—SLC22A3—embryo—muscle cancer	0.00319	0.017	CbGeAlD
Procainamide—DNMT1—vagina—muscle cancer	0.0031	0.0165	CbGeAlD
Procainamide—SCN4A—tendon—muscle cancer	0.00304	0.0162	CbGeAlD
Procainamide—SCN3A—renal system—muscle cancer	0.00303	0.0161	CbGeAlD
Procainamide—Sunitinib—KIT—muscle cancer	0.00287	1	CrCbGaD
Procainamide—DNMT1—head—muscle cancer	0.00286	0.0153	CbGeAlD
Procainamide—SCN9A—testis—muscle cancer	0.00282	0.015	CbGeAlD
Procainamide—DNMT1—testis—muscle cancer	0.00277	0.0148	CbGeAlD
Procainamide—ACHE—tendon—muscle cancer	0.00271	0.0145	CbGeAlD
Procainamide—SCN5A—cardiac atrium—muscle cancer	0.0027	0.0144	CbGeAlD
Procainamide—SLC22A4—renal system—muscle cancer	0.00265	0.0141	CbGeAlD
Procainamide—SCN4A—head—muscle cancer	0.0026	0.0139	CbGeAlD
Procainamide—SLC22A1—renal system—muscle cancer	0.00252	0.0135	CbGeAlD
Procainamide—SCN4A—testis—muscle cancer	0.00252	0.0134	CbGeAlD
Procainamide—SCN1A—head—muscle cancer	0.00251	0.0134	CbGeAlD
Procainamide—SLC22A3—smooth muscle tissue—muscle cancer	0.00251	0.0134	CbGeAlD
Procainamide—SCN2A—vagina—muscle cancer	0.0025	0.0133	CbGeAlD
Procainamide—SLC22A3—renal system—muscle cancer	0.00241	0.0129	CbGeAlD
Procainamide—SCN3A—tendon—muscle cancer	0.00236	0.0126	CbGeAlD
Procainamide—SCN2A—head—muscle cancer	0.00231	0.0123	CbGeAlD
Procainamide—SCN3A—bone marrow—muscle cancer	0.00229	0.0122	CbGeAlD
Procainamide—Pericarditis—Methotrexate—muscle cancer	0.00229	0.0224	CcSEcCtD
Procainamide—ACHE—testis—muscle cancer	0.00225	0.012	CbGeAlD
Procainamide—SCN10A—head—muscle cancer	0.00222	0.0119	CbGeAlD
Procainamide—SCN3A—vagina—muscle cancer	0.00219	0.0117	CbGeAlD
Procainamide—SCN5A—vagina—muscle cancer	0.00219	0.0117	CbGeAlD
Procainamide—SLC22A4—tendon—muscle cancer	0.00207	0.011	CbGeAlD
Procainamide—SCN3A—head—muscle cancer	0.00203	0.0108	CbGeAlD
Procainamide—SCN5A—head—muscle cancer	0.00202	0.0108	CbGeAlD
Procainamide—DNMT1—Regulation of retinoblastoma protein—MYOD1—muscle cancer	0.00201	0.0393	CbGpPWpGaD
Procainamide—SLC22A4—bone marrow—muscle cancer	0.002	0.0107	CbGeAlD
Procainamide—Pericarditis—Doxorubicin—muscle cancer	0.00198	0.0194	CcSEcCtD
Procainamide—SCN3A—testis—muscle cancer	0.00196	0.0104	CbGeAlD
Procainamide—SLC22A4—vagina—muscle cancer	0.00192	0.0102	CbGeAlD
Procainamide—Hepatic failure—Dactinomycin—muscle cancer	0.00184	0.0181	CcSEcCtD
Procainamide—SLC22A1—vagina—muscle cancer	0.00183	0.00975	CbGeAlD
Procainamide—BCHE—smooth muscle tissue—muscle cancer	0.00178	0.00947	CbGeAlD
Procainamide—SLC22A5—renal system—muscle cancer	0.00175	0.00936	CbGeAlD
Procainamide—SLC22A3—vagina—muscle cancer	0.00175	0.00932	CbGeAlD
Procainamide—CHRM2—head—muscle cancer	0.00172	0.00917	CbGeAlD
Procainamide—Lethargy—Dactinomycin—muscle cancer	0.00169	0.0166	CcSEcCtD
Procainamide—SLC22A1—head—muscle cancer	0.00169	0.00901	CbGeAlD
Procainamide—Hepatic failure—Vincristine—muscle cancer	0.00165	0.0162	CcSEcCtD
Procainamide—SLC22A3—head—muscle cancer	0.00161	0.00861	CbGeAlD
Procainamide—SLC22A5—cardiac atrium—muscle cancer	0.00157	0.00838	CbGeAlD
Procainamide—SLC22A3—testis—muscle cancer	0.00156	0.00832	CbGeAlD
Procainamide—BCHE—cardiac atrium—muscle cancer	0.00153	0.00816	CbGeAlD
Procainamide—Rash maculo-papular—Etoposide—muscle cancer	0.0015	0.0147	CcSEcCtD
Procainamide—Cardiac arrest—Vincristine—muscle cancer	0.00141	0.0138	CcSEcCtD
Procainamide—SLC22A5—tendon—muscle cancer	0.00137	0.0073	CbGeAlD
Procainamide—Neutropenia—Dactinomycin—muscle cancer	0.00134	0.0131	CcSEcCtD
Procainamide—SCN7A—Developmental Biology—MYF6—muscle cancer	0.00133	0.026	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—MYF5—muscle cancer	0.00133	0.026	CbGpPWpGaD
Procainamide—BCHE—bone marrow—muscle cancer	0.00129	0.00689	CbGeAlD
Procainamide—Pleural effusion—Methotrexate—muscle cancer	0.00129	0.0127	CcSEcCtD
Procainamide—SLC22A5—vagina—muscle cancer	0.00127	0.00678	CbGeAlD
Procainamide—BCHE—vagina—muscle cancer	0.00124	0.0066	CbGeAlD
Procainamide—Cardiac failure—Etoposide—muscle cancer	0.00123	0.0121	CcSEcCtD
Procainamide—Hepatomegaly—Doxorubicin—muscle cancer	0.00121	0.0119	CcSEcCtD
Procainamide—Neutropenia—Vincristine—muscle cancer	0.0012	0.0117	CcSEcCtD
Procainamide—Agranulocytosis—Dactinomycin—muscle cancer	0.00119	0.0117	CcSEcCtD
Procainamide—SCN11A—Developmental Biology—MYF6—muscle cancer	0.00119	0.0232	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—MYF5—muscle cancer	0.00119	0.0232	CbGpPWpGaD
Procainamide—BCHE—head—muscle cancer	0.00114	0.0061	CbGeAlD
Procainamide—Cardiac arrest—Etoposide—muscle cancer	0.00114	0.0112	CcSEcCtD
Procainamide—Depression—Vincristine—muscle cancer	0.00114	0.0112	CcSEcCtD
Procainamide—SLC22A5—testis—muscle cancer	0.00113	0.00605	CbGeAlD
Procainamide—CYP2D6—renal system—muscle cancer	0.00113	0.00604	CbGeAlD
Procainamide—Pleural effusion—Doxorubicin—muscle cancer	0.00112	0.011	CcSEcCtD
Procainamide—BCHE—testis—muscle cancer	0.0011	0.00589	CbGeAlD
Procainamide—SCN8A—Developmental Biology—MYF5—muscle cancer	0.00109	0.0212	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—MYF6—muscle cancer	0.00109	0.0212	CbGpPWpGaD
Procainamide—Oliguria—Methotrexate—muscle cancer	0.00107	0.0105	CcSEcCtD
Procainamide—Flushing—Dactinomycin—muscle cancer	0.00106	0.0104	CcSEcCtD
Procainamide—Hepatic enzyme increased—Methotrexate—muscle cancer	0.00105	0.0103	CcSEcCtD
Procainamide—Chills—Dactinomycin—muscle cancer	0.00103	0.0101	CcSEcCtD
Procainamide—Hallucination—Vincristine—muscle cancer	0.00102	0.01	CcSEcCtD
Procainamide—Vasculitis—Methotrexate—muscle cancer	0.00101	0.00994	CcSEcCtD
Procainamide—Neutropenia—Etoposide—muscle cancer	0.000969	0.00951	CcSEcCtD
Procainamide—Cardiac disorder—Vincristine—muscle cancer	0.00095	0.00932	CcSEcCtD
Procainamide—Oliguria—Doxorubicin—muscle cancer	0.00093	0.00912	CcSEcCtD
Procainamide—Ill-defined disorder—Dactinomycin—muscle cancer	0.000926	0.00908	CcSEcCtD
Procainamide—Renal failure—Etoposide—muscle cancer	0.000908	0.00891	CcSEcCtD
Procainamide—Malaise—Dactinomycin—muscle cancer	0.0009	0.00883	CcSEcCtD
Procainamide—SCN9A—Developmental Biology—MYF5—muscle cancer	0.000878	0.0171	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—MYF6—muscle cancer	0.000878	0.0171	CbGpPWpGaD
Procainamide—Agranulocytosis—Etoposide—muscle cancer	0.000862	0.00846	CcSEcCtD
Procainamide—SCN7A—Developmental Biology—MYOG—muscle cancer	0.000858	0.0168	CbGpPWpGaD
Procainamide—Ventricular tachycardia—Doxorubicin—muscle cancer	0.000857	0.00841	CcSEcCtD
Procainamide—Myalgia—Dactinomycin—muscle cancer	0.000849	0.00833	CcSEcCtD
Procainamide—SCN3A—Developmental Biology—MYF6—muscle cancer	0.000839	0.0164	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—MYF5—muscle cancer	0.000839	0.0164	CbGpPWpGaD
Procainamide—Discomfort—Dactinomycin—muscle cancer	0.000839	0.00823	CcSEcCtD
Procainamide—SCN4A—Developmental Biology—MYF6—muscle cancer	0.000806	0.0158	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MYF6—muscle cancer	0.000806	0.0158	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MYF5—muscle cancer	0.000806	0.0158	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—MYF5—muscle cancer	0.000806	0.0158	CbGpPWpGaD
Procainamide—ACHE—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000802	0.0157	CbGpPWpGaD
Procainamide—Hepatic failure—Methotrexate—muscle cancer	0.000799	0.00784	CcSEcCtD
Procainamide—Thrombocytopenia—Dactinomycin—muscle cancer	0.000797	0.00782	CcSEcCtD
Procainamide—Rash maculo-papular—Doxorubicin—muscle cancer	0.000779	0.00764	CcSEcCtD
Procainamide—SCN1A—Developmental Biology—MYF5—muscle cancer	0.000778	0.0152	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—MYF6—muscle cancer	0.000778	0.0152	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MYF5—muscle cancer	0.000778	0.0152	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MYF6—muscle cancer	0.000778	0.0152	CbGpPWpGaD
Procainamide—Anorexia—Dactinomycin—muscle cancer	0.000776	0.00761	CcSEcCtD
Procainamide—Convulsion—Vincristine—muscle cancer	0.000772	0.00758	CcSEcCtD
Procainamide—Cardiac disorder—Etoposide—muscle cancer	0.00077	0.00755	CcSEcCtD
Procainamide—Flushing—Etoposide—muscle cancer	0.00077	0.00755	CcSEcCtD
Procainamide—SCN11A—Developmental Biology—MYOG—muscle cancer	0.000765	0.0149	CbGpPWpGaD
Procainamide—Myalgia—Vincristine—muscle cancer	0.000759	0.00744	CcSEcCtD
Procainamide—CYP2D6—head—muscle cancer	0.000757	0.00404	CbGeAlD
Procainamide—Chills—Etoposide—muscle cancer	0.000744	0.0073	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000742	0.00728	CcSEcCtD
Procainamide—Lethargy—Methotrexate—muscle cancer	0.000733	0.00719	CcSEcCtD
Procainamide—CYP2D6—testis—muscle cancer	0.000732	0.0039	CbGeAlD
Procainamide—Thrombocytopenia—Vincristine—muscle cancer	0.000712	0.00699	CcSEcCtD
Procainamide—SCN5A—Cardiac Progenitor Differentiation—IGF2—muscle cancer	0.000708	0.0138	CbGpPWpGaD
Procainamide—Decreased appetite—Dactinomycin—muscle cancer	0.000708	0.00694	CcSEcCtD
Procainamide—Dysgeusia—Etoposide—muscle cancer	0.000707	0.00694	CcSEcCtD
Procainamide—SCN8A—Developmental Biology—MYOG—muscle cancer	0.000699	0.0137	CbGpPWpGaD
Procainamide—Anorexia—Vincristine—muscle cancer	0.000693	0.0068	CcSEcCtD
Procainamide—Hepatic failure—Doxorubicin—muscle cancer	0.000692	0.00679	CcSEcCtD
Procainamide—Hypotension—Vincristine—muscle cancer	0.00068	0.00667	CcSEcCtD
Procainamide—SCN5A—SIDS Susceptibility Pathways—TP73—muscle cancer	0.000671	0.0131	CbGpPWpGaD
Procainamide—Feeling abnormal—Dactinomycin—muscle cancer	0.000671	0.00658	CcSEcCtD
Procainamide—Ill-defined disorder—Etoposide—muscle cancer	0.00067	0.00657	CcSEcCtD
Procainamide—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000666	0.00653	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000663	0.0065	CcSEcCtD
Procainamide—Renal impairment—Doxorubicin—muscle cancer	0.000653	0.00641	CcSEcCtD
Procainamide—Malaise—Etoposide—muscle cancer	0.000651	0.00639	CcSEcCtD
Procainamide—Body temperature increased—Dactinomycin—muscle cancer	0.000644	0.00631	CcSEcCtD
Procainamide—Abdominal pain—Dactinomycin—muscle cancer	0.000644	0.00631	CcSEcCtD
Procainamide—Cardiac failure—Doxorubicin—muscle cancer	0.000637	0.00625	CcSEcCtD
Procainamide—Lethargy—Doxorubicin—muscle cancer	0.000635	0.00623	CcSEcCtD
Procainamide—Decreased appetite—Vincristine—muscle cancer	0.000632	0.0062	CcSEcCtD
Procainamide—Convulsion—Etoposide—muscle cancer	0.000626	0.00614	CcSEcCtD
Procainamide—DNMT1—Regulation of retinoblastoma protein—CDKN2A—muscle cancer	0.000624	0.0122	CbGpPWpGaD
Procainamide—Eosinophilia—Methotrexate—muscle cancer	0.000615	0.00603	CcSEcCtD
Procainamide—Discomfort—Etoposide—muscle cancer	0.000607	0.00596	CcSEcCtD
Procainamide—DNMT1—Regulation of retinoblastoma protein—MDM2—muscle cancer	0.000605	0.0118	CbGpPWpGaD
Procainamide—Hypersensitivity—Dactinomycin—muscle cancer	0.0006	0.00589	CcSEcCtD
Procainamide—Abdominal discomfort—Methotrexate—muscle cancer	0.000595	0.00584	CcSEcCtD
Procainamide—Gastrointestinal pain—Vincristine—muscle cancer	0.000595	0.00584	CcSEcCtD
Procainamide—Confusional state—Etoposide—muscle cancer	0.000594	0.00583	CcSEcCtD
Procainamide—Cardiac arrest—Doxorubicin—muscle cancer	0.000591	0.0058	CcSEcCtD
Procainamide—Asthenia—Dactinomycin—muscle cancer	0.000584	0.00573	CcSEcCtD
Procainamide—Neutropenia—Methotrexate—muscle cancer	0.00058	0.00569	CcSEcCtD
Procainamide—Thrombocytopenia—Etoposide—muscle cancer	0.000577	0.00566	CcSEcCtD
Procainamide—Body temperature increased—Vincristine—muscle cancer	0.000575	0.00564	CcSEcCtD
Procainamide—Abdominal pain—Vincristine—muscle cancer	0.000575	0.00564	CcSEcCtD
Procainamide—Abdominal pain upper—Doxorubicin—muscle cancer	0.000568	0.00557	CcSEcCtD
Procainamide—SCN9A—Developmental Biology—MYOG—muscle cancer	0.000566	0.011	CbGpPWpGaD
Procainamide—Anorexia—Etoposide—muscle cancer	0.000562	0.00551	CcSEcCtD
Procainamide—Diarrhoea—Dactinomycin—muscle cancer	0.000557	0.00547	CcSEcCtD
Procainamide—Depression—Methotrexate—muscle cancer	0.000552	0.00541	CcSEcCtD
Procainamide—Hypotension—Etoposide—muscle cancer	0.000551	0.0054	CcSEcCtD
Procainamide—SCN5A—Developmental Biology—MYF5—muscle cancer	0.000547	0.0107	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MYF6—muscle cancer	0.000547	0.0107	CbGpPWpGaD
Procainamide—Renal failure—Methotrexate—muscle cancer	0.000544	0.00534	CcSEcCtD
Procainamide—SCN3A—Developmental Biology—MYOG—muscle cancer	0.000541	0.0106	CbGpPWpGaD
Procainamide—Hypersensitivity—Vincristine—muscle cancer	0.000536	0.00526	CcSEcCtD
Procainamide—Eosinophilia—Doxorubicin—muscle cancer	0.000532	0.00522	CcSEcCtD
Procainamide—SCN7A—Developmental Biology—MYOD1—muscle cancer	0.00053	0.0103	CbGpPWpGaD
Procainamide—Asthenia—Vincristine—muscle cancer	0.000522	0.00512	CcSEcCtD
Procainamide—SCN4A—Developmental Biology—MYOG—muscle cancer	0.00052	0.0101	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MYOG—muscle cancer	0.00052	0.0101	CbGpPWpGaD
Procainamide—Vomiting—Dactinomycin—muscle cancer	0.000518	0.00508	CcSEcCtD
Procainamide—Agranulocytosis—Methotrexate—muscle cancer	0.000516	0.00507	CcSEcCtD
Procainamide—Decreased appetite—Etoposide—muscle cancer	0.000512	0.00503	CcSEcCtD
Procainamide—Neutropenia—Doxorubicin—muscle cancer	0.000503	0.00493	CcSEcCtD
Procainamide—SCN1A—Developmental Biology—MYOG—muscle cancer	0.000501	0.00979	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MYOG—muscle cancer	0.000501	0.00979	CbGpPWpGaD
Procainamide—Diarrhoea—Vincristine—muscle cancer	0.000498	0.00488	CcSEcCtD
Procainamide—SCN5A—Cardiac Progenitor Differentiation—KIT—muscle cancer	0.000497	0.0097	CbGpPWpGaD
Procainamide—Feeling abnormal—Etoposide—muscle cancer	0.000486	0.00476	CcSEcCtD
Procainamide—DNMT1—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000485	0.00948	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—MED12—muscle cancer	0.000485	0.00947	CbGpPWpGaD
Procainamide—Nausea—Dactinomycin—muscle cancer	0.000484	0.00474	CcSEcCtD
Procainamide—Gastrointestinal pain—Etoposide—muscle cancer	0.000482	0.00473	CcSEcCtD
Procainamide—Dizziness—Vincristine—muscle cancer	0.000481	0.00472	CcSEcCtD
Procainamide—SCN11A—Developmental Biology—MYOD1—muscle cancer	0.000472	0.00922	CbGpPWpGaD
Procainamide—Renal failure—Doxorubicin—muscle cancer	0.000471	0.00462	CcSEcCtD
Procainamide—Urticaria—Etoposide—muscle cancer	0.000468	0.00459	CcSEcCtD
Procainamide—Abdominal pain—Etoposide—muscle cancer	0.000466	0.00457	CcSEcCtD
Procainamide—Body temperature increased—Etoposide—muscle cancer	0.000466	0.00457	CcSEcCtD
Procainamide—Vomiting—Vincristine—muscle cancer	0.000463	0.00454	CcSEcCtD
Procainamide—Cardiac disorder—Methotrexate—muscle cancer	0.000461	0.00452	CcSEcCtD
Procainamide—Agranulocytosis—Doxorubicin—muscle cancer	0.000447	0.00439	CcSEcCtD
Procainamide—Chills—Methotrexate—muscle cancer	0.000446	0.00437	CcSEcCtD
Procainamide—Bradycardia—Doxorubicin—muscle cancer	0.000438	0.0043	CcSEcCtD
Procainamide—Hypersensitivity—Etoposide—muscle cancer	0.000434	0.00426	CcSEcCtD
Procainamide—Nausea—Vincristine—muscle cancer	0.000432	0.00424	CcSEcCtD
Procainamide—SCN11A—Developmental Biology—MED12—muscle cancer	0.000432	0.00844	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—MYOD1—muscle cancer	0.000432	0.00844	CbGpPWpGaD
Procainamide—Dysgeusia—Methotrexate—muscle cancer	0.000424	0.00416	CcSEcCtD
Procainamide—Asthenia—Etoposide—muscle cancer	0.000423	0.00415	CcSEcCtD
Procainamide—ACHE—Metabolism of proteins—TIMM10—muscle cancer	0.000423	0.00825	CbGpPWpGaD
Procainamide—Pruritus—Etoposide—muscle cancer	0.000417	0.00409	CcSEcCtD
Procainamide—Diarrhoea—Etoposide—muscle cancer	0.000403	0.00396	CcSEcCtD
Procainamide—Ill-defined disorder—Methotrexate—muscle cancer	0.000401	0.00394	CcSEcCtD
Procainamide—Cardiac disorder—Doxorubicin—muscle cancer	0.000399	0.00392	CcSEcCtD
Procainamide—Flushing—Doxorubicin—muscle cancer	0.000399	0.00392	CcSEcCtD
Procainamide—SCN8A—Developmental Biology—MED12—muscle cancer	0.000395	0.00772	CbGpPWpGaD
Procainamide—Malaise—Methotrexate—muscle cancer	0.00039	0.00383	CcSEcCtD
Procainamide—Dizziness—Etoposide—muscle cancer	0.00039	0.00382	CcSEcCtD
Procainamide—Chills—Doxorubicin—muscle cancer	0.000386	0.00379	CcSEcCtD
Procainamide—BCHE—Metabolism of proteins—TIMM10—muscle cancer	0.000377	0.00736	CbGpPWpGaD
Procainamide—Convulsion—Methotrexate—muscle cancer	0.000375	0.00368	CcSEcCtD
Procainamide—Vomiting—Etoposide—muscle cancer	0.000375	0.00368	CcSEcCtD
Procainamide—Arthralgia—Methotrexate—muscle cancer	0.000368	0.00361	CcSEcCtD
Procainamide—Myalgia—Methotrexate—muscle cancer	0.000368	0.00361	CcSEcCtD
Procainamide—Dysgeusia—Doxorubicin—muscle cancer	0.000367	0.0036	CcSEcCtD
Procainamide—Discomfort—Methotrexate—muscle cancer	0.000364	0.00357	CcSEcCtD
Procainamide—Confusional state—Methotrexate—muscle cancer	0.000356	0.00349	CcSEcCtD
Procainamide—SCN5A—Developmental Biology—MYOG—muscle cancer	0.000352	0.00688	CbGpPWpGaD
Procainamide—Nausea—Etoposide—muscle cancer	0.00035	0.00343	CcSEcCtD
Procainamide—SCN9A—Developmental Biology—MYOD1—muscle cancer	0.000349	0.00682	CbGpPWpGaD
Procainamide—Ill-defined disorder—Doxorubicin—muscle cancer	0.000347	0.00341	CcSEcCtD
Procainamide—CHRM2—SIDS Susceptibility Pathways—TP73—muscle cancer	0.000346	0.00676	CbGpPWpGaD
Procainamide—Thrombocytopenia—Methotrexate—muscle cancer	0.000346	0.00339	CcSEcCtD
Procainamide—Malaise—Doxorubicin—muscle cancer	0.000338	0.00331	CcSEcCtD
Procainamide—Anorexia—Methotrexate—muscle cancer	0.000336	0.0033	CcSEcCtD
Procainamide—SCN3A—Developmental Biology—MYOD1—muscle cancer	0.000334	0.00653	CbGpPWpGaD
Procainamide—Hypotension—Methotrexate—muscle cancer	0.00033	0.00324	CcSEcCtD
Procainamide—CYP2D6—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000329	0.00642	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000329	0.00642	CbGpPWpGaD
Procainamide—Convulsion—Doxorubicin—muscle cancer	0.000324	0.00318	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000322	0.00316	CcSEcCtD
Procainamide—SCN4A—Developmental Biology—MYOD1—muscle cancer	0.000321	0.00627	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MYOD1—muscle cancer	0.000321	0.00627	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—MED12—muscle cancer	0.00032	0.00624	CbGpPWpGaD
Procainamide—Myalgia—Doxorubicin—muscle cancer	0.000319	0.00313	CcSEcCtD
Procainamide—Arthralgia—Doxorubicin—muscle cancer	0.000319	0.00313	CcSEcCtD
Procainamide—Discomfort—Doxorubicin—muscle cancer	0.000315	0.00309	CcSEcCtD
Procainamide—SCN1A—Developmental Biology—MYOD1—muscle cancer	0.00031	0.00605	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MYOD1—muscle cancer	0.00031	0.00605	CbGpPWpGaD
Procainamide—Confusional state—Doxorubicin—muscle cancer	0.000308	0.00302	CcSEcCtD
Procainamide—Decreased appetite—Methotrexate—muscle cancer	0.000307	0.00301	CcSEcCtD
Procainamide—SCN3A—Developmental Biology—MED12—muscle cancer	0.000306	0.00597	CbGpPWpGaD
Procainamide—Shock—Doxorubicin—muscle cancer	0.000301	0.00295	CcSEcCtD
Procainamide—Thrombocytopenia—Doxorubicin—muscle cancer	0.000299	0.00294	CcSEcCtD
Procainamide—SCN4A—Developmental Biology—MED12—muscle cancer	0.000294	0.00574	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MED12—muscle cancer	0.000294	0.00574	CbGpPWpGaD
Procainamide—Anorexia—Doxorubicin—muscle cancer	0.000291	0.00286	CcSEcCtD
Procainamide—Feeling abnormal—Methotrexate—muscle cancer	0.000291	0.00285	CcSEcCtD
Procainamide—CHRM2—GPCRs, Other—CNR1—muscle cancer	0.00029	0.00566	CbGpPWpGaD
Procainamide—Gastrointestinal pain—Methotrexate—muscle cancer	0.000289	0.00283	CcSEcCtD
Procainamide—Hypotension—Doxorubicin—muscle cancer	0.000286	0.0028	CcSEcCtD
Procainamide—SCN10A—Developmental Biology—MED12—muscle cancer	0.000283	0.00553	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—MED12—muscle cancer	0.000283	0.00553	CbGpPWpGaD
Procainamide—Urticaria—Methotrexate—muscle cancer	0.00028	0.00275	CcSEcCtD
Procainamide—Abdominal pain—Methotrexate—muscle cancer	0.000279	0.00274	CcSEcCtD
Procainamide—Body temperature increased—Methotrexate—muscle cancer	0.000279	0.00274	CcSEcCtD
Procainamide—DNMT1—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	0.000279	0.00544	CbGpPWpGaD
Procainamide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000278	0.00273	CcSEcCtD
Procainamide—SCN7A—Developmental Biology—FOXO1—muscle cancer	0.000266	0.0052	CbGpPWpGaD
Procainamide—Decreased appetite—Doxorubicin—muscle cancer	0.000266	0.00261	CcSEcCtD
Procainamide—Hypersensitivity—Methotrexate—muscle cancer	0.00026	0.00255	CcSEcCtD
Procainamide—Asthenia—Methotrexate—muscle cancer	0.000253	0.00248	CcSEcCtD
Procainamide—Feeling abnormal—Doxorubicin—muscle cancer	0.000252	0.00247	CcSEcCtD
Procainamide—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00025	0.00245	CcSEcCtD
Procainamide—Pruritus—Methotrexate—muscle cancer	0.00025	0.00245	CcSEcCtD
Procainamide—Urticaria—Doxorubicin—muscle cancer	0.000243	0.00238	CcSEcCtD
Procainamide—Body temperature increased—Doxorubicin—muscle cancer	0.000242	0.00237	CcSEcCtD
Procainamide—Abdominal pain—Doxorubicin—muscle cancer	0.000242	0.00237	CcSEcCtD
Procainamide—Diarrhoea—Methotrexate—muscle cancer	0.000241	0.00237	CcSEcCtD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.00024	0.00469	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—FOXO1—muscle cancer	0.000237	0.00463	CbGpPWpGaD
Procainamide—Dizziness—Methotrexate—muscle cancer	0.000233	0.00229	CcSEcCtD
Procainamide—Hypersensitivity—Doxorubicin—muscle cancer	0.000225	0.00221	CcSEcCtD
Procainamide—Vomiting—Methotrexate—muscle cancer	0.000224	0.0022	CcSEcCtD
Procainamide—Asthenia—Doxorubicin—muscle cancer	0.000219	0.00215	CcSEcCtD
Procainamide—SCN5A—Developmental Biology—MYOD1—muscle cancer	0.000218	0.00425	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—FOXO1—muscle cancer	0.000217	0.00424	CbGpPWpGaD
Procainamide—Pruritus—Doxorubicin—muscle cancer	0.000216	0.00212	CcSEcCtD
Procainamide—Nausea—Methotrexate—muscle cancer	0.00021	0.00206	CcSEcCtD
Procainamide—Diarrhoea—Doxorubicin—muscle cancer	0.000209	0.00205	CcSEcCtD
Procainamide—Dizziness—Doxorubicin—muscle cancer	0.000202	0.00198	CcSEcCtD
Procainamide—SCN5A—Developmental Biology—MED12—muscle cancer	0.000199	0.00389	CbGpPWpGaD
Procainamide—Vomiting—Doxorubicin—muscle cancer	0.000194	0.00191	CcSEcCtD
Procainamide—DNMT1—Gene Expression—MED12—muscle cancer	0.000188	0.00367	CbGpPWpGaD
Procainamide—Nausea—Doxorubicin—muscle cancer	0.000182	0.00178	CcSEcCtD
Procainamide—SCN9A—Developmental Biology—FOXO1—muscle cancer	0.000175	0.00343	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—VEGFA—muscle cancer	0.00017	0.00332	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—FOXO1—muscle cancer	0.000168	0.00328	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—FOXO1—muscle cancer	0.000161	0.00315	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—FOXO1—muscle cancer	0.000161	0.00315	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—FOXO1—muscle cancer	0.000155	0.00304	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—FOXO1—muscle cancer	0.000155	0.00304	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—VEGFA—muscle cancer	0.000151	0.00296	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—VEGFA—muscle cancer	0.000138	0.0027	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—CNR1—muscle cancer	0.000136	0.00265	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—FH—muscle cancer	0.000135	0.00264	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000135	0.00264	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000126	0.00246	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.000125	0.00245	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—VEGFA—muscle cancer	0.000121	0.00237	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.00012	0.00235	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—VEGFA—muscle cancer	0.000112	0.00219	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—FOXO1—muscle cancer	0.000109	0.00213	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—VEGFA—muscle cancer	0.000108	0.00211	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000108	0.00211	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—VEGFA—muscle cancer	0.000107	0.00209	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000106	0.00208	CbGpPWpGaD
Procainamide—ACHE—Metabolism—FH—muscle cancer	0.000106	0.00208	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—VEGFA—muscle cancer	0.000103	0.00201	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—VEGFA—muscle cancer	0.000103	0.00201	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000103	0.002	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000103	0.002	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—VEGFA—muscle cancer	9.92e-05	0.00194	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—VEGFA—muscle cancer	9.92e-05	0.00194	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—VEGFA—muscle cancer	9.88e-05	0.00193	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—PTCH1—muscle cancer	9.73e-05	0.0019	CbGpPWpGaD
Procainamide—BCHE—Metabolism—FH—muscle cancer	9.49e-05	0.00185	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—MDM2—muscle cancer	9.15e-05	0.00179	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—FH—muscle cancer	8.48e-05	0.00166	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CNR1—muscle cancer	8.22e-05	0.0016	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—MDM2—muscle cancer	8.18e-05	0.0016	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	8.08e-05	0.00158	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—VEGFA—muscle cancer	7.99e-05	0.00156	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—FH—muscle cancer	7.9e-05	0.00154	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—MDM2—muscle cancer	7.86e-05	0.00154	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—VEGFA—muscle cancer	7.64e-05	0.00149	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—MED12—muscle cancer	7.64e-05	0.00149	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—MDM2—muscle cancer	7.62e-05	0.00149	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KIDINS220—muscle cancer	7.5e-05	0.00146	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—VEGFA—muscle cancer	7.34e-05	0.00143	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—VEGFA—muscle cancer	7.34e-05	0.00143	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—VEGFA—muscle cancer	7.08e-05	0.00138	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—VEGFA—muscle cancer	7.08e-05	0.00138	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—MDM2—muscle cancer	7.01e-05	0.00137	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—VEGFA—muscle cancer	6.98e-05	0.00136	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ENO2—muscle cancer	6.96e-05	0.00136	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—IGF2—muscle cancer	6.96e-05	0.00136	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—VEGFA—muscle cancer	6.46e-05	0.00126	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—MDM2—muscle cancer	6.26e-05	0.00122	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—IGF2—muscle cancer	6.21e-05	0.00121	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	6.11e-05	0.00119	CbGpPWpGaD
Procainamide—ACHE—Metabolism—MED12—muscle cancer	6.01e-05	0.00117	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—MDM2—muscle cancer	5.84e-05	0.00114	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ENO2—muscle cancer	5.48e-05	0.00107	CbGpPWpGaD
Procainamide—BCHE—Metabolism—MED12—muscle cancer	5.36e-05	0.00105	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PTCH1—muscle cancer	5e-05	0.000976	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—VEGFA—muscle cancer	4.98e-05	0.000972	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ENO2—muscle cancer	4.89e-05	0.000955	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—MED12—muscle cancer	4.79e-05	0.000935	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CNR1—muscle cancer	4.64e-05	0.000907	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—MED12—muscle cancer	4.46e-05	0.000872	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ENO2—muscle cancer	4.37e-05	0.000853	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—FH—muscle cancer	4.36e-05	0.000852	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.29e-05	0.000837	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CNR1—muscle cancer	4.22e-05	0.000824	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ENO2—muscle cancer	4.07e-05	0.000795	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.82e-05	0.000747	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTCH1—muscle cancer	2.95e-05	0.000576	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FOXO4—muscle cancer	2.54e-05	0.000496	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CNR1—muscle cancer	2.49e-05	0.000487	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—MED12—muscle cancer	2.47e-05	0.000482	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTGS2—muscle cancer	2.42e-05	0.000474	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ENO2—muscle cancer	2.25e-05	0.000439	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IGF2—muscle cancer	2.04e-05	0.000398	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTGS2—muscle cancer	1.91e-05	0.000373	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FOXO1—muscle cancer	1.87e-05	0.000366	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTGS2—muscle cancer	1.7e-05	0.000333	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTGS2—muscle cancer	1.52e-05	0.000297	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KIT—muscle cancer	1.43e-05	0.000279	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTGS2—muscle cancer	1.42e-05	0.000277	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MDM2—muscle cancer	1.12e-05	0.00022	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—VEGFA—muscle cancer	8.54e-06	0.000167	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTGS2—muscle cancer	7.83e-06	0.000153	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TP53—muscle cancer	6.45e-06	0.000126	CbGpPWpGaD
